Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hellmann

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Journal of Chemotherapy (Florence, Italy)|December 1, 1989
ICRF 187K Hellmann
Seminars in Oncology|October 13, 1998
Overview and historical development of dexrazoxaneK Hellmann
The Lancet. Oncology|March 22, 2002
Angiogenesis: tumour size is no guide to malignancyK Hellmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critiqueK Hellmann
Clinical & Experimental Metastasis|January 1, 1984
Antimetastatic drugs: laboratory to clinicK Hellmann
EXS|January 1, 1992
Angiogenesis--time to review progressK Hellmann
Proceedings of the Royal Society of Medicine|February 1, 1974
Investigational drugs for the treatment of malignant melanomaK Hellmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic indexK Hellmann
Proceedings of the Royal Society of Medicine|March 1, 1972
Effect of ICRF 159 on immune responsesK Hellmann
Praxis Der Pneumologie|December 1, 1974
[The pneumonology professional practice today]K Hellmann
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Journal of Chemotherapy (Florence, Italy)|December 1, 1989
ICRF 187K Hellmann
Seminars in Oncology|October 13, 1998
Overview and historical development of dexrazoxaneK Hellmann
The Lancet. Oncology|March 22, 2002
Angiogenesis: tumour size is no guide to malignancyK Hellmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critiqueK Hellmann
Clinical & Experimental Metastasis|January 1, 1984
Antimetastatic drugs: laboratory to clinicK Hellmann
EXS|January 1, 1992
Angiogenesis--time to review progressK Hellmann
Proceedings of the Royal Society of Medicine|February 1, 1974
Investigational drugs for the treatment of malignant melanomaK Hellmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic indexK Hellmann
Proceedings of the Royal Society of Medicine|March 1, 1972
Effect of ICRF 159 on immune responsesK Hellmann
Praxis Der Pneumologie|December 1, 1974
[The pneumonology professional practice today]K Hellmann
Pageof 12